drugset / Trial / NCT06047431
A Study of QL1706H in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is an open-label, Phase Ⅰ study of QL1706H in patients with advanced solid tumors. The study will evaluate the pharmacokenetics, safety, tolerability and preliminary efficacy of QL1706H.
Timeline
- Start
- 2023-10
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706H | Monoclonal antibody | — | Subcutaneous |